These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition. Maciola AK; La Raja M; Pacenti M; Salata C; De Silvestro G; Rosato A; Pasqual G Front Immunol; 2022; 13():830710. PubMed ID: 35173741 [TBL] [Abstract][Full Text] [Related]
3. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Legros V; Denolly S; Vogrig M; Boson B; Siret E; Rigaill J; Pillet S; Grattard F; Gonzalo S; Verhoeven P; Allatif O; Berthelot P; Pélissier C; Thiery G; Botelho-Nevers E; Millet G; Morel J; Paul S; Walzer T; Cosset FL; Bourlet T; Pozzetto B Cell Mol Immunol; 2021 Feb; 18(2):318-327. PubMed ID: 33408342 [TBL] [Abstract][Full Text] [Related]
5. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers. Irsara C; Egger AE; Prokop W; Nairz M; Loacker L; Sahanic S; Pizzini A; Sonnweber T; Holzer B; Mayer W; Schennach H; Loeffler-Ragg J; Bellmann-Weiler R; Hartmann B; Tancevski I; Weiss G; Binder CJ; Anliker M; Griesmacher A; Hoermann G Clin Chem Lab Med; 2021 Jul; 59(8):1453-1462. PubMed ID: 33837679 [TBL] [Abstract][Full Text] [Related]
6. Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma. Tso FY; Lidenge SJ; Poppe LK; Peña PB; Privatt SR; Bennett SJ; Ngowi JR; Mwaiselage J; Belshan M; Siedlik JA; Raine MA; Ochoa JB; Garcia-Diaz J; Nossaman B; Buckner L; Roberts WM; Dean MJ; Ochoa AC; West JT; Wood C PLoS One; 2021; 16(3):e0247640. PubMed ID: 33661923 [TBL] [Abstract][Full Text] [Related]
7. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects. Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein. Tani H; Kimura M; Tan L; Yoshida Y; Ozawa T; Kishi H; Fukushi S; Saijo M; Sano K; Suzuki T; Kawasuji H; Ueno A; Miyajima Y; Fukui Y; Sakamaki I; Yamamoto Y; Morinaga Y Virol J; 2021 Jan; 18(1):16. PubMed ID: 33435994 [TBL] [Abstract][Full Text] [Related]
9. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736 [TBL] [Abstract][Full Text] [Related]
10. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China. Feng X; Yin J; Zhang J; Hu Y; Ouyang Y; Qiao S; Zhao H; Zhang T; Li X; Zhang L; Zhang J; Jin R; Feng Y; Su B Front Immunol; 2021; 12():614436. PubMed ID: 33790892 [TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity. Kim JY; Kwon JS; Bae S; Cha HH; Lim JS; Kim MC; Chung JW; Park SY; Lee MJ; Kim BN; Jung J; Kim MJ; Shin EC; Kim SH Am J Trop Med Hyg; 2021 Jun; 105(2):395-400. PubMed ID: 34143752 [TBL] [Abstract][Full Text] [Related]
12. The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein. Chen X; Rostad CA; Anderson LJ; Sun HY; Lapp SA; Stephens K; Hussaini L; Gibson T; Rouphael N; Anderson EJ Virology; 2021 Jul; 559():1-9. PubMed ID: 33774551 [TBL] [Abstract][Full Text] [Related]
13. Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. Butler SE; Crowley AR; Natarajan H; Xu S; Weiner JA; Bobak CA; Mattox DE; Lee J; Wieland-Alter W; Connor RI; Wright PF; Ackerman ME Front Immunol; 2020; 11():618685. PubMed ID: 33584712 [TBL] [Abstract][Full Text] [Related]
14. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History. Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S Front Immunol; 2021; 12():793191. PubMed ID: 34975897 [TBL] [Abstract][Full Text] [Related]
15. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients. Ruetalo N; Businger R; Althaus K; Fink S; Ruoff F; Pogoda M; Iftner A; Ganzenmüller T; Hamprecht K; Flehmig B; Bakchoul T; Templin MF; Schindler M mSphere; 2021 Feb; 6(1):. PubMed ID: 33627511 [TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study. Trieu MC; Bansal A; Madsen A; Zhou F; Sævik M; Vahokoski J; Brokstad KA; Krammer F; Tøndel C; Mohn KGI; Blomberg B; Langeland N; Cox RJ; J Infect Dis; 2021 Feb; 223(4):589-599. PubMed ID: 33247924 [TBL] [Abstract][Full Text] [Related]
17. Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients. Tang J; Ravichandran S; Lee Y; Grubbs G; Coyle EM; Klenow L; Genser H; Golding H; Khurana S Nat Commun; 2021 Feb; 12(1):1221. PubMed ID: 33619281 [TBL] [Abstract][Full Text] [Related]